目的 探討通心絡(luò)膠囊聯(lián)合阿羅洛爾治療冠心病心絞痛的臨床療效。方法 選取2022年4月—2025年3月在華北醫(yī)療健康集團(tuán)峰峰總醫(yī)院治療的冠心病心絞痛患者96例，按隨機(jī)數(shù)字表法分為對照組和治療組，每組各48例。對照組口服鹽酸阿羅洛爾片，10 mg/次，2次/d。治療組以對照組方案為基礎(chǔ)口服通心絡(luò)膠囊，3粒/次，3次/d。兩組患者療程8周。觀察兩組患者臨床療效，比較治療前后兩組患者心電圖ST-T改善率，心絞痛發(fā)作程度、時長和次數(shù)，Duke、簡式抑郁-焦慮-壓力量表（DASS-21）和中國心血管病人生活質(zhì)量評定問卷（CQQC）評分，及抗凝血酶Ⅲ（AT-Ⅲ）、D-二聚體（D-D）、系統(tǒng)免疫炎癥指數(shù)（SII）和血清白細(xì)胞介素-7（IL-7）和缺血修飾白蛋白（IMA）水平。結(jié)果 治療后，治療組總有效率為93.75%，明顯高于對照組的79.17%，兩組比較差異具有統(tǒng)計學(xué)意義（P＜0.05）。治療后，治療組心電圖ST-T改善率（87.50%）顯著高于對照組（68.75%，P＜0.05）。兩組患者心絞痛程度、時長、次數(shù)都低于組內(nèi)治療前（P＜0.05），且以治療組改善更明顯（P＜0.05）。治療后，兩組Duke、CQQC評分均高于組內(nèi)治療前，而DASS-21評分均下降（P＜0.05），且治療后治療組患者評分明顯好于對照組（P＜0.05）。治療后，兩組AT-Ⅲ水平都高于組內(nèi)治療前，而D-D、SII和血清IL-7、IMA水平均降低（P＜0.05），且治療組患者上述指標(biāo)水平明顯好于對照組（P＜0.05）。結(jié)論 在冠心病心絞痛的治療中應(yīng)用通心絡(luò)膠囊與阿羅洛爾的聯(lián)合方案，能進(jìn)一步控制機(jī)體的凝血異常，緩解炎癥反應(yīng)及心肌缺血狀態(tài)，促進(jìn)患者心絞痛表現(xiàn)和預(yù)后好轉(zhuǎn)，對其心理狀態(tài)和生活質(zhì)量有積極影響。

Objective To explore the clinical efficacy of Tongxinluo Capsules combined with arotinolol in treatment of angina pectoris in coronary heart disease. Methods Patients (96 cases) with angina pectoris in coronary heart disease in Fengfeng General Hospital, North China Medical and Health Group from April 2022 to March 2025 were divided into control and treatment group according to random number table method, and each group had 48 cases. Patients in the control group were po administered with Arotinolol Hydrochloride Tablets, 10 mg/time, twice daily. Patients in the treatment group were po administered with Tongxinluo Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical evaluations were evaluated, and the improvement of ECG ST-T, degree, duration and frequency of angina attacks, the scores of Duke, DASS-21 and CQQC, the levels of AT-Ⅲ, D-D, SII, IL-7 and IMA in two groups before and after treatment were compared. Results After treatment, the total effective rate in the treatment group was 93.75%, which was significantly higher than that in the control group (79.17%), and the difference between the two groups was statistically significant (P < 0.05). After treatment, the improvement rate of ECG ST-T in the treatment group (87.50%) was significantly higher than that in the control group (68.75%, P < 0.05). The severity, duration and frequency of angina pectoris in two groups were lower than before treatment (P < 0.05), and the improvement was more obvious in the treatment group (P < 0.05). After treatment, Duke and CQQC scores in two groups were higher than those before treatment, while DASS-21 scores were decreased (P < 0.05). After treatment, the scores in the treatment group were significantly better than those in the control group (P < 0.05). After treatment, the levels of AT-Ⅲ in two groups were higher than those before treatment, while the levels of D-D, SII and serum IL-7 and IMA were all reduced (P < 0.05), and the levels of these indicators in the treatment group were significantly better than those in the control group (P < 0.05). Conclusion The combination of Tongxinluo Capsules and arotinolol in treatment of angina pectoris in coronary heart disease can further control coagulation abnormalities, alleviate inflammatory reactions and myocardial ischemia, promote the improvement of angina symptoms and prognosis in patients, and have a positive impact on their psychological state and quality of life.

R972

邯鄲市科技專項計劃自籌經(jīng)費項目（22422083092）